• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

市售脱矿骨基质的骨诱导活性。脊柱融合模型中的制剂

Osteoinductivity of commercially available demineralized bone matrix. Preparations in a spine fusion model.

作者信息

Peterson Brett, Whang Peter G, Iglesias Roberto, Wang Jeff C, Lieberman Jay R

机构信息

Department of Orthopaedic Surgery, David Geffen School of Medicine at UCLA, Center for Health Sciences 76-134, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA.

出版信息

J Bone Joint Surg Am. 2004 Oct;86(10):2243-50. doi: 10.2106/00004623-200410000-00016.

DOI:10.2106/00004623-200410000-00016
PMID:15466734
Abstract

BACKGROUND

Although autogenous bone is the most widely used graft material for spinal fusion, demineralized bone matrix preparations are available as alternatives or supplements to autograft. They are prepared by acid extraction of most of the mineralized component, with retention of the collagen and noncollagenous proteins, including growth factors. Differences in allograft processing methods among suppliers might yield products with different osteoinductive activities. The purpose of this study was to compare the efficacy of three different commercially available demineralized bone matrix products for inducing spinal fusion in an athymic rat model.

METHODS

Sixty male athymic rats underwent spinal fusion and were divided into three groups of eighteen animals each. Group I received Grafton Putty; Group II, DBX Putty; and Group III, AlloMatrix Injectable Putty. A control group of six animals (Group IV) underwent decortication alone. Six animals from each of the three experimental groups were killed at each of three intervals (two, four, and eight weeks), and the six animals from the control group were killed at eight weeks. At each of the time-points, radiographic and histologic analysis and manual testing of the explanted spines were performed.

RESULTS

The spines in Group I demonstrated higher rates of radiographically evident fusion at eight weeks than did the spines in Group III or Group IV (p < 0.05). Manual testing of the spines at four weeks revealed variable fusion rates (five of six in Group I, two of six in Group II, and none of six in Group III). At eight weeks, all six spines in Group I, three of the six in Group II, and no spine in Group III or IV had fused. Histologic analysis of the spines in Groups I, II, and III demonstrated varying amounts of residual demineralized bone matrix and new bone formation. Group-I spines demonstrated the most new bone formation.

CONCLUSIONS

This study demonstrated differences in the osteoinductive potentials of commercially available demineralized bone matrices in this animal model.

摘要

背景

尽管自体骨是脊柱融合术中应用最广泛的移植材料,但脱矿骨基质制剂可作为自体移植的替代物或补充物。它们是通过酸提取大部分矿化成分而制备的,保留了胶原蛋白和非胶原蛋白,包括生长因子。供应商之间同种异体移植物处理方法的差异可能会产生具有不同骨诱导活性的产品。本研究的目的是比较三种不同市售脱矿骨基质产品在无胸腺大鼠模型中诱导脊柱融合的疗效。

方法

60只雄性无胸腺大鼠接受脊柱融合术,并分为三组,每组18只动物。第一组接受Grafton Putty;第二组接受DBX Putty;第三组接受AlloMatrix可注射腻子。一个由6只动物组成的对照组(第四组)仅接受去皮质术。三个实验组中的每组6只动物在三个时间间隔(两周、四周和八周)的每个时间点处死,对照组的6只动物在八周时处死。在每个时间点,对外植脊柱进行影像学和组织学分析以及手动测试。

结果

第一组的脊柱在八周时影像学上明显融合的发生率高于第三组或第四组(p < 0.05)。四周时对脊柱进行手动测试发现融合率各不相同(第一组6只中有5只,第二组6只中有2只,第三组6只中无融合)。八周时,第一组的所有6只脊柱、第二组的6只中有3只、第三组或第四组中无脊柱融合。对第一组、第二组和第三组的脊柱进行组织学分析显示,残留的脱矿骨基质和新骨形成的量各不相同。第一组的脊柱显示出新骨形成最多。

结论

本研究证明了在该动物模型中,市售脱矿骨基质的骨诱导潜力存在差异。

相似文献

1
Osteoinductivity of commercially available demineralized bone matrix. Preparations in a spine fusion model.市售脱矿骨基质的骨诱导活性。脊柱融合模型中的制剂
J Bone Joint Surg Am. 2004 Oct;86(10):2243-50. doi: 10.2106/00004623-200410000-00016.
2
Efficacy comparison of Accell Evo3 and Grafton demineralized bone matrix putties against autologous bone in a rat posterolateral spine fusion model.在大鼠后外侧脊柱融合模型中,Accell Evo3和Grafton脱矿骨基质糊剂与自体骨的疗效比较。
Spine J. 2017 Jun;17(6):855-862. doi: 10.1016/j.spinee.2017.01.012. Epub 2017 Jan 23.
3
Local effect of zoledronic acid on new bone formation in posterolateral spinal fusion with demineralized bone matrix in a murine model.唑来膦酸对小鼠模型中使用脱矿骨基质进行后外侧脊柱融合时新骨形成的局部作用。
Arch Orthop Trauma Surg. 2018 Jan;138(1):13-18. doi: 10.1007/s00402-017-2818-4. Epub 2017 Oct 10.
4
The efficacy of different commercially available demineralized bone matrix substances in an athymic rat model.不同市售脱矿骨基质物质在无胸腺大鼠模型中的疗效。
J Spinal Disord Tech. 2005 Oct;18(5):439-44. doi: 10.1097/01.bsd.0000175696.66049.f7.
5
Evidence of osteoinduction by Grafton demineralized bone matrix in nonhuman primate spinal fusion.Grafton脱矿骨基质在非人灵长类动物脊柱融合中骨诱导作用的证据。
Spine (Phila Pa 1976). 2004 Feb 15;29(4):360-6; discussion Z1. doi: 10.1097/01.brs.0000090823.12652.f9.
6
Evaluation of a new formulation of demineralized bone matrix putty in a rabbit posterolateral spinal fusion model.在兔后外侧脊柱融合模型中对一种新型脱矿骨基质糊剂配方的评估。
Spine J. 2014 Sep 1;14(9):2155-63. doi: 10.1016/j.spinee.2014.01.053. Epub 2014 Feb 8.
7
New formulations of demineralized bone matrix as a more effective graft alternative in experimental posterolateral lumbar spine arthrodesis.脱矿骨基质的新配方作为实验性腰椎后外侧脊柱融合术中更有效的移植替代物。
Spine (Phila Pa 1976). 1999 Apr 1;24(7):637-45. doi: 10.1097/00007632-199904010-00005.
8
A comparison of commercially available demineralized bone matrix for spinal fusion.用于脊柱融合的市售脱矿骨基质的比较。
Eur Spine J. 2007 Aug;16(8):1233-40. doi: 10.1007/s00586-006-0282-x. Epub 2007 Jan 5.
9
Augmentation of rabbit posterolateral spondylodesis using a novel demineralized bone matrix-hyaluronan putty.使用新型脱矿骨基质-透明质酸糊剂增强兔后外侧脊柱融合术
Spine (Phila Pa 1976). 2003 Nov 1;28(21):2435-40. doi: 10.1097/01.BRS.0000090828.65638.8C.
10
Experimental posterolateral lumbar spinal fusion with a demineralized bone matrix gel.使用脱矿骨基质凝胶进行实验性腰椎后外侧脊柱融合术。
Spine (Phila Pa 1976). 1998 Jan 15;23(2):159-67. doi: 10.1097/00007632-199801150-00003.

引用本文的文献

1
Regional Gene Therapy for Bone Tissue Engineering: A Current Concepts Review.骨组织工程的区域基因治疗:当前概念综述
Bioengineering (Basel). 2025 Jan 27;12(2):120. doi: 10.3390/bioengineering12020120.
2
From Basic Science to Clinical Practice: A Review of Current Periodontal/Mucogingival Regenerative Biomaterials.从基础科学到临床实践:当前牙周/黏骨膜再生生物材料的综述。
Adv Sci (Weinh). 2024 May;11(17):e2308848. doi: 10.1002/advs.202308848. Epub 2024 Feb 21.
3
Self-Assembled Nanocomposite Hydrogels as Carriers for Demineralized Bone Matrix Particles and Enhanced Bone Repair.
自组装纳米复合水凝胶作为脱矿骨基质颗粒的载体和增强骨修复。
Adv Healthc Mater. 2024 Apr;13(10):e2303592. doi: 10.1002/adhm.202303592. Epub 2024 Feb 11.
4
Decellularized extracellular matrix materials for treatment of ischemic cardiomyopathy.用于治疗缺血性心肌病的脱细胞细胞外基质材料
Bioact Mater. 2023 Nov 29;33:460-482. doi: 10.1016/j.bioactmat.2023.10.015. eCollection 2024 Mar.
5
Inducing Angiogenesis in the Nucleus Pulposus.诱导髓核血管生成。
Cells. 2023 Oct 19;12(20):2488. doi: 10.3390/cells12202488.
6
Current concepts of bone grafting in trauma surgery.创伤外科中骨移植的当前概念。
J Clin Orthop Trauma. 2023 Aug 5;43:102231. doi: 10.1016/j.jcot.2023.102231. eCollection 2023 Aug.
7
The impact of demineralized bone matrix characteristics on pseudarthrosis and surgical outcomes after posterolateral lumbar decompression and fusion.脱矿骨基质特征对腰椎后外侧减压融合术后假关节形成及手术效果的影响。
J Craniovertebr Junction Spine. 2023 Apr-Jun;14(2):194-200. doi: 10.4103/jcvjs.jcvjs_45_23. Epub 2023 Jun 13.
8
The Clinical Use of Osteobiologic and Metallic Biomaterials in Orthopedic Surgery: The Present and the Future.骨生物材料和金属生物材料在骨科手术中的临床应用:现状与未来。
Materials (Basel). 2023 May 10;16(10):3633. doi: 10.3390/ma16103633.
9
Advances Focusing on the Application of Decellularized Extracellular Matrix in Periodontal Regeneration.关注脱细胞细胞外基质在牙周再生中应用的进展。
Biomolecules. 2023 Apr 14;13(4):673. doi: 10.3390/biom13040673.
10
Comparison of demineralized bone matrix with different cycling crushing times in posterolateral fusion model of athymic rats.去胸腺大鼠后外侧融合模型中不同循环粉碎时间的脱矿骨基质比较
Cell Tissue Bank. 2023 Dec;24(4):747-758. doi: 10.1007/s10561-023-10086-0. Epub 2023 May 3.